Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK2 | Q16620 | 4/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | KCNJ6 | P48051 | 8/20 | 0.41 |
| ▸ | KCNJ3 | P48549 | 8/20 | 0.41 |
| ▸ | KCNJ5 | P48544 | 4/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.38 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.38 |
| ▸ | TEK | Q02763 | 3/20 | 0.38 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1924036 | 0.88 | NTRK1 (0.57) | NTRK2NTRK1PIK3CDKCNJ6KCNJ3 | |
| SCHEMBL1925959 | 0.87 | NTRK1 (0.50) | NTRK2NTRK1PIK3CDKCNJ6KCNJ3 | |
| SCHEMBL1924527 | 0.87 | NTRK1 (0.56) | NTRK2NTRK1PIK3CDKCNJ6KCNJ3 | |
| SCHEMBL14537179 | 0.86 | NTRK2 (0.56) | NTRK2NTRK1PIK3CDEGFRERBB2 | |
| SCHEMBL1924646 | 0.86 | NTRK1 (0.73) | NTRK2NTRK1PIK3CDKCNJ6KCNJ3 | |
| SCHEMBL1926391 | 0.82 | AURKB (0.55) | NTRK2NTRK1PIK3CDKCNJ6KCNJ3 | |
| SCHEMBL13885180 | 0.79 | NTRK2 (0.83) | NTRK2NTRK1EGFRERBB2ERBB3 | |
| SCHEMBL1924683 | 0.79 | KCNJ6 (0.49) | NTRK2NTRK1PIK3CDKCNJ6KCNJ3 | |
| SCHEMBL12537701 | 0.77 | NTRK2 (0.55) | NTRK2NTRK1PDGFRBAURKAAURKB | |
| SCHEMBL12537482 | 0.76 | NTRK2 (0.53) | NTRK2NTRK1PIK3CDCSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948664-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-06-08 | — | — | EP | disclosed |
| US-7514435-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | NTRK2, NTRK3, NTRK1 | NTRK2 1/4885NTRK1 3/4885PIK3CD 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.